Chong Kun Dang Pharmaceutical
Clinical trials sponsored by Chong Kun Dang Pharmaceutical, explained in plain language.
Pharmaceutical company producing prescription drugs and healthcare products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cheaper psoriasis drug on the horizon? new biosimilar enters human trials Results expected Sep 2026 (estimated)
- Can a new blood pressure pill match the original? Results expected Oct 2026 (estimated)
- New biosimilar aims to offer cheaper eczema treatment Results expected Nov 2026 (estimated)
- New hope for advanced cancer patients: experimental drug CKD-512 enters human trials Results expected Mar 2027 (estimated)
- New drug combo for BRCA ovarian cancer enters early testing Results expected Jun 2027 (estimated)
-
Can a new blood pressure pill match the original?
Disease control Not yet recruitingThis trial is testing two experimental versions of a blood pressure drug, called D311 and D107, against the original medication, CKD-339. Healthy adults aged 19 to 55 will receive a single dose of each version in a random order to compare how the drug is absorbed and processed in…
Phase 1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo for BRCA ovarian cancer enters early testing
Disease control Not yet recruitingThis early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…
Phase 1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo therapy aims to control diabetes without side effects
Disease control Not yet recruitingThis study compares two different drug combinations for people with type 2 diabetes whose blood sugar is not well controlled with metformin and sitagliptin. About 200 adults will receive either empagliflozin or glimepiride added to their current treatment. The goal is to see whic…
Phase 4 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC